Market Cap 5.22B
Revenue (ttm) 1.36B
Net Income (ttm) 120.36M
EPS (ttm) N/A
PE Ratio 26.06
Forward PE 27.99
Profit Margin 8.87%
Debt to Equity Ratio 0.48
Volume 1,194,402
Avg Vol 641,960
Day's Range N/A - N/A
Shares Out 59.29M
Stochastic %K 43%
Beta 0.64
Analysts Strong Sell
Price Target $104.40

Company Profile

Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as verte...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Phone: 801 253 1600
Fax: 801 253 1652
Address:
1600 West Merit Parkway, South Jordan, United States
JarvisFlow
JarvisFlow Nov. 14 at 8:30 PM
Barrington Research updates rating for Merit Medical Systems ( $MMSI ) to Outperform, target set at 106.
0 · Reply
JarvisFlow
JarvisFlow Nov. 14 at 5:49 PM
Canaccord Genuity has updated their rating for Merit Medical Systems ( $MMSI ) to Buy with a price target of 93.
0 · Reply
JarvisFlow
JarvisFlow Nov. 14 at 3:13 PM
Wells Fargo has updated their rating for Merit Medical Systems ( $MMSI ) to Overweight with a price target of 95.
0 · Reply
OpenOutcrier
OpenOutcrier Nov. 14 at 1:32 PM
$MMSI (-4.5% pre) Merit Medical withdraws reimbursement application, pivots strategy https://ooc.bz/l/84556
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 4:34 AM
$MMSI: The last close at $87.4 indicates a strong position within the recent trading range. The RSI at 64.78 suggests that the stock is nearing overbought territory, which may limit upside potential in the short term. The MA30 at $84.14 and MA50 at $84.42 provide solid support levels, indicating bullish momentum. The proximity to the 60D high of $93.27 suggests potential resistance ahead, while the 60D low of $78.12 indicates a well-defined range. Directional bias is cautiously bullish, given the strong support from moving averages and the recent price action. Suggested entry is at $88.00, slightly above the last close to capture momentum. Set a stop loss at $85.50 to manage risk. Target 1 is $91.00, approaching the 60D high, while Target 2 is $93.00, just below the 60D high for a conservative exit. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 2:40 AM
$MMSI: The last close at $89.39 indicates a strong position above the 30-day MA of $83.78 and the 50-day MA of $84.55, suggesting bullish momentum. The RSI of 65.66 indicates the stock is nearing overbought territory but is not yet excessively so, allowing for potential upward movement. The recent 60-day high of $93.27 provides a resistance level, while the low of $78.12 establishes a solid support base. Directional bias is bullish given the price action above key moving averages and the proximity to the recent high. Suggested entry: $89.50 (slightly above last close to confirm momentum). Stop: $87.00 (below recent support levels). Targets: $92.00 (near the 60D high) and $94.00 (a psychological level). Monitor for any signs of reversal as the stock approaches resistance. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 2:16 AM
$MMSI: The last close at $89.39 indicates a strong position above the 30-day MA of $83.78 and the 50-day MA of $84.55, suggesting bullish momentum. The RSI of 65.66 indicates the stock is nearing overbought territory but is not yet excessively so, allowing for potential upward movement. The recent 60-day high of $93.27 provides a resistance level, while the low of $78.12 establishes a solid support base. Directional bias is bullish given the price action above key moving averages and the proximity to the recent high. Suggested entry: $89.50 (slightly above last close to confirm momentum). Stop: $87.00 (below recent support levels). Targets: $92.00 (near the 60D high) and $94.00 (a psychological level). Monitor for any signs of reversal as the stock approaches resistance. https://privateprofiteers.com
0 · Reply
SuperGreenToday
SuperGreenToday Nov. 7 at 6:54 PM
$MMSI Share Price: $87.79 Contract Selected: Apr 17, 2026 $85 Calls Buy Zone: $6.80 – $8.40 Target Zone: $10.89 – $13.31 Potential Upside: 51% ROI Time to Expiration: 160 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
RunnerSignals
RunnerSignals Nov. 1 at 9:00 PM
$MEDP $CCJ $TEVA $TM $MMSI are heating up this week with breakouts and fresh volume spikes. see which charts traders are watching next https://stocksrunner.com/news/2025-11-01-top-momentum-stock-picks-on-the-rise
0 · Reply
ZacksResearch
ZacksResearch Oct. 31 at 6:12 PM
$MMSI beats Q3 estimates — bullish setup ahead? 🚀 👍 Adjusted EPS up 6.9%, topping estimates by 12.2% 📈 Revenue rose 13% on a reported basis, beating projections by 3.5% 🇺🇸 Strong growth in U.S. and international sales Discover why MMSI’s outlook is brightening 👉 https://www.zacks.com/stock/news/2782907/merit-medical-q3-earnings-revenues-beat-estimate-margins-expand?cid=sm-stocktwits-2-2782907-body-18845&ADID=SYND_STOCKTWITS_TWEET_2_2782907_BODY_18845
0 · Reply
Latest News on MMSI
Merit Medical Has To Rebuild Some Confidence In The Growth Story

Sep 9, 2025, 12:18 AM EDT - 2 months ago

Merit Medical Has To Rebuild Some Confidence In The Growth Story


The Market Is Vulnerable. 6 ‘Defensive' Stocks to Buy Now.

Jun 9, 2025, 12:46 PM EDT - 5 months ago

The Market Is Vulnerable. 6 ‘Defensive' Stocks to Buy Now.

CRM EXC MSI


Merit Medical Acquires Biolife Delaware, L.L.C.

May 20, 2025, 7:30 AM EDT - 6 months ago

Merit Medical Acquires Biolife Delaware, L.L.C.


Merit Medical Launches the Ventrax™ Delivery System

Apr 9, 2025, 9:25 AM EDT - 7 months ago

Merit Medical Launches the Ventrax™ Delivery System


Merit Medical: A Success Story That Keeps Getting Better

Mar 16, 2025, 12:34 PM EDT - 8 months ago

Merit Medical: A Success Story That Keeps Getting Better


First Patient Enrolled in Merit Medical's PREEMIE Study

Mar 10, 2025, 9:25 AM EDT - 8 months ago

First Patient Enrolled in Merit Medical's PREEMIE Study


Merit Medical Announces Resignation of President, Joseph Wright

Dec 16, 2024, 4:00 PM EST - 11 months ago

Merit Medical Announces Resignation of President, Joseph Wright


Merit Medical Launches basixSKY™ Inflation Device

May 21, 2024, 9:25 AM EDT - 1 year ago

Merit Medical Launches basixSKY™ Inflation Device


Merit Medical Executive Leadership Team Update

May 15, 2024, 4:05 PM EDT - 1 year ago

Merit Medical Executive Leadership Team Update


JarvisFlow
JarvisFlow Nov. 14 at 8:30 PM
Barrington Research updates rating for Merit Medical Systems ( $MMSI ) to Outperform, target set at 106.
0 · Reply
JarvisFlow
JarvisFlow Nov. 14 at 5:49 PM
Canaccord Genuity has updated their rating for Merit Medical Systems ( $MMSI ) to Buy with a price target of 93.
0 · Reply
JarvisFlow
JarvisFlow Nov. 14 at 3:13 PM
Wells Fargo has updated their rating for Merit Medical Systems ( $MMSI ) to Overweight with a price target of 95.
0 · Reply
OpenOutcrier
OpenOutcrier Nov. 14 at 1:32 PM
$MMSI (-4.5% pre) Merit Medical withdraws reimbursement application, pivots strategy https://ooc.bz/l/84556
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 4:34 AM
$MMSI: The last close at $87.4 indicates a strong position within the recent trading range. The RSI at 64.78 suggests that the stock is nearing overbought territory, which may limit upside potential in the short term. The MA30 at $84.14 and MA50 at $84.42 provide solid support levels, indicating bullish momentum. The proximity to the 60D high of $93.27 suggests potential resistance ahead, while the 60D low of $78.12 indicates a well-defined range. Directional bias is cautiously bullish, given the strong support from moving averages and the recent price action. Suggested entry is at $88.00, slightly above the last close to capture momentum. Set a stop loss at $85.50 to manage risk. Target 1 is $91.00, approaching the 60D high, while Target 2 is $93.00, just below the 60D high for a conservative exit. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 2:40 AM
$MMSI: The last close at $89.39 indicates a strong position above the 30-day MA of $83.78 and the 50-day MA of $84.55, suggesting bullish momentum. The RSI of 65.66 indicates the stock is nearing overbought territory but is not yet excessively so, allowing for potential upward movement. The recent 60-day high of $93.27 provides a resistance level, while the low of $78.12 establishes a solid support base. Directional bias is bullish given the price action above key moving averages and the proximity to the recent high. Suggested entry: $89.50 (slightly above last close to confirm momentum). Stop: $87.00 (below recent support levels). Targets: $92.00 (near the 60D high) and $94.00 (a psychological level). Monitor for any signs of reversal as the stock approaches resistance. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 2:16 AM
$MMSI: The last close at $89.39 indicates a strong position above the 30-day MA of $83.78 and the 50-day MA of $84.55, suggesting bullish momentum. The RSI of 65.66 indicates the stock is nearing overbought territory but is not yet excessively so, allowing for potential upward movement. The recent 60-day high of $93.27 provides a resistance level, while the low of $78.12 establishes a solid support base. Directional bias is bullish given the price action above key moving averages and the proximity to the recent high. Suggested entry: $89.50 (slightly above last close to confirm momentum). Stop: $87.00 (below recent support levels). Targets: $92.00 (near the 60D high) and $94.00 (a psychological level). Monitor for any signs of reversal as the stock approaches resistance. https://privateprofiteers.com
0 · Reply
SuperGreenToday
SuperGreenToday Nov. 7 at 6:54 PM
$MMSI Share Price: $87.79 Contract Selected: Apr 17, 2026 $85 Calls Buy Zone: $6.80 – $8.40 Target Zone: $10.89 – $13.31 Potential Upside: 51% ROI Time to Expiration: 160 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
RunnerSignals
RunnerSignals Nov. 1 at 9:00 PM
$MEDP $CCJ $TEVA $TM $MMSI are heating up this week with breakouts and fresh volume spikes. see which charts traders are watching next https://stocksrunner.com/news/2025-11-01-top-momentum-stock-picks-on-the-rise
0 · Reply
ZacksResearch
ZacksResearch Oct. 31 at 6:12 PM
$MMSI beats Q3 estimates — bullish setup ahead? 🚀 👍 Adjusted EPS up 6.9%, topping estimates by 12.2% 📈 Revenue rose 13% on a reported basis, beating projections by 3.5% 🇺🇸 Strong growth in U.S. and international sales Discover why MMSI’s outlook is brightening 👉 https://www.zacks.com/stock/news/2782907/merit-medical-q3-earnings-revenues-beat-estimate-margins-expand?cid=sm-stocktwits-2-2782907-body-18845&ADID=SYND_STOCKTWITS_TWEET_2_2782907_BODY_18845
0 · Reply
ZacksResearch
ZacksResearch Oct. 31 at 5:12 PM
$MMSI crushes Q3 expectations 🔥 Strong revenue and expanding margins drove the beat, leading management to raise full-year guidance across multiple segments. Full earnings breakdown here 👉 https://www.zacks.com/stock/news/2782907/merit-medical-q3-earnings-revenues-beat-estimate-margins-expand?cid=sm-stocktwits-2-2782907-teaser-18824&ADID=SYND_STOCKTWITS_TWEET_2_2782907_TEASER_18824
0 · Reply
Lowlow1
Lowlow1 Oct. 27 at 1:00 PM
$MMSI ydkg is going to pop at its 52 low rising looking good,.,....just take a look.,...,...,...........hurry up#@
0 · Reply
prismmarketview
prismmarketview Oct. 16 at 1:28 PM
(NASDAQ: $MMSI) #MeritMedical announced a $22M deal to acquire the C2 CryoBalloon technology from Pentax of America, expanding its endoscopy portfolio. The minimally invasive GI device targets Barrett’s esophagus and GERD. https://prismmarketview.com/merit-medical-expands-gi-portfolio-with-22m-acquisition-of-c2-cryoballoon-technology/
0 · Reply
ZacksResearch
ZacksResearch Oct. 16 at 1:20 PM
$MMSI set to expand with C2 CryoBalloon acquisition — long-term growth play in GI market? 💡 📉 Stock down 16.8% YTD vs. industry’s 1.9% decline 💰 $22M deal opens doors to multibillion-dollar gastroenterology segment 📈 Revenue contributions expected to ramp up in 2026, despite near-term earnings pressure Discover the strategic move here 👉 https://www.zacks.com/stock/news/2769967/merit-medical-expands-gi-portfolio-with-22m-c2-cryoballoon-acquisition?cid=sm-stocktwits-2-2769967-body-16313&ADID=SYND_STOCKTWITS_TWEET_2_2769967_BODY_16313
0 · Reply
OpenOutcrier
OpenOutcrier Oct. 16 at 12:45 PM
$MMSI (+1.9% pre) C2 CryoBalloon product line sold to Merit Medical; PENTAX Medical refocuses on flexible reusable endoscopy https://ooc.bz/l/80764
0 · Reply
ZacksResearch
ZacksResearch Oct. 16 at 12:21 PM
$MMSI just made a bold move into GI growth territory 👀 The $22M acquisition of C2 CryoBalloon from Pentax expands its gastroenterology lineup — a short-term hit, but a long-term play for stronger positioning in the GI market. See the full growth rationale here 👉 https://www.zacks.com/stock/news/2769967/merit-medical-expands-gi-portfolio-with-22m-c2-cryoballoon-acquisition?cid=sm-stocktwits-2-2769967-teaser-16312&ADID=SYND_STOCKTWITS_TWEET_2_2769967_TEASER_16312
0 · Reply
JarvisFlow
JarvisFlow Oct. 16 at 11:20 AM
Canaccord Genuity has updated their rating for Merit Medical Systems ( $MMSI ) to Buy with a price target of 104.
0 · Reply
DonCorleone77
DonCorleone77 Oct. 15 at 8:26 PM
$MMSI Merit Medical to acquire C2 CryoBalloon device for $22M, sees dilution
0 · Reply
BearScout
BearScout Oct. 5 at 12:12 PM
$MMSI Healthcare technology growth. Testing resistance level. Volume confirmation needed. Sector momentum building.
0 · Reply
JarvisFlow
JarvisFlow Sep. 23 at 3:19 PM
Barrington Research updates rating for Merit Medical Systems ( $MMSI ) to Outperform, target set at 103.
0 · Reply
ZacksResearch
ZacksResearch Sep. 15 at 6:24 PM
$MMSI secures a CE Mark for knee OA treatment — shares plunged 5.2%, but not due to the news. 🤔 🔹 Expanded market opportunity with Embosphere for genicular artery embolisation 🔹 Proven tech with 25+ years of clinical use 🔹 Shares still down 11.6% YTD despite industry decline of 1.8% What’s next for MMSI? Full breakdown here 👉 https://www.zacks.com/stock/news/2751711/mmsi-stock-falls-despite-ce-mark-win-for-embosphere-in-knee-oa-care?cid=sm-stocktwits-2-2751711-body-12511&ADID=SYND_STOCKTWITS_TWEET_2_2751711_BODY_12511
0 · Reply
ZacksResearch
ZacksResearch Sep. 15 at 5:24 PM
$MMSI drops even after a CE Mark win — what gives? ⚠️ The company just secured approval to expand Embosphere into knee osteoarthritis care, offering a minimally invasive treatment option. See the full bull/bear setup here 👉 https://www.zacks.com/stock/news/2751711/mmsi-stock-falls-despite-ce-mark-win-for-embosphere-in-knee-oa-care?cid=sm-stocktwits-2-2751711-teaser-12507&ADID=SYND_STOCKTWITS_TWEET_2_2751711_TEASER_12507
0 · Reply